Intensity-modulated radiation therapy with hypoxic sensitizer AK-2123 (Sanazole) for glioblastoma multiforme using simultaneous integrated boost technique intensity-modulated radiation therapy with hypoxic sensitizer AK-2123 (Sanazole) for glioblastoma multiforme using simultaneous integrated boost technique

摘要

Background: Glioblastoma has a very poor prognosis even after incorporation into therapy of the newly-developed drug, temozolomide. Case Report: We present a case of 62-year-old woman with glioblastoma multiforme treated with tomotherapy intensity-modulated radiation therapy using simultaneous integrated boost technique (SIB-IMRT) along with a daily oral dose of a hypoxic radiation sensitizer, sanazole (AK-2123). SIB-IMRT was administered at a dose of 60 Gy in 20 fractions for high-risk planning target volume (PTV) and at 40 Gy for low-risk PTV. The patient received an oral administration of sanazole (1.0 g/day) for 10 days, 2 h before radiotherapy. She achieved a complete response without any adverse events, and remained disease-free for 3.5 years. Our study demonstrates that the higher single-dose radiotherapy combined with a hypoxic radiation sensitizer has the potential to enhance the efficacy of radiotherapy.